FM8 860
European Association of Urology recommendations for grading of NMIBC indicate that
both the 1973WHO and the 2004/2016WHO classification should be used until new
international multicentre studies and individual patient data analyses assess the real
prognostic value of the 1973 and 2004/2016WHO classifications.
814
Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical MorbidityS. Syan-Bhanvadia, S.T. Bazargani, T.G. Clifford, J. Cai, G. Miranda, S. Daneshmand
A midline extraperitoneal approach to retroperitoneal lymph node dissection is
feasible and offers excellent exposure, even in the setting of large masses. It is
associated with early return of bowel function and discharge, and minimizes the
long-term risk of small bowel obstruction.
821
Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians’ Health StudyM.K. Downer, C.B. Allard, M.A. Preston, J.M. Gaziano, M.J. Stampfer, L.A. Mucci, J.L. Batista
Our study examined the potential effect of regular aspirin use on lethal prostate
cancer. We found that taking aspirin reduced the risk of lethal prostate cancer, and
taking it after diagnosis may help prevent prostate cancer from becoming fatal.
828
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and EnzalutamideA.K. Seitz, S. Thoene, A. Bietenbeck, R. Nawroth, R. Tauber, M. Thalgott, S. Schmid, R. Secci,
M. Retz, J.E. Gschwend, J. Ruland, C. Winter, M.M. Heck
We established a robust liquid profiling approach for direct quantification of AR-V7
transcript levels in peripheral whole blood. This test predicted treatment resistance in
patients with metastatic castration-resistant prostate cancer undergoing treatment
with abiraterone or enzalutamide. Prospective validation is needed before
application to clinical practice.
835
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer ProgressionR. Wang, Y. Sun, L. Li, Y. Niu, W. Lin, C. Lin, E.S. Antonarakis, J. Luo, S. Yeh, C. Chang
Malat1
expression is linked to the enhanced androgen receptor splicing variant 7
expression, and their induction may play key roles in the development of
enzalutamide resistance.
Malat1
and the androgen receptor splicing variant 7 could
serve as clinically relevant therapeutic targets for patients who received
enzalutamide treatment and targeting AR-v7 with ASC-J9
®
may further suppress
enzalutamide resistant prostate cancer.
845
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy SpecimensP.L. Nguyen, Z. Haddad, A.E. Ross, N.E. Martin, S. Deheshi, L.L.C. Lam, J. Chelliserry, J.J. Tosoian,
T.L. Lotan, D.E. Spratt, R.S. Stoyanova, S. Punnen, K. Ong, C. Buerki, M. Aranes, T. Kolisnik,
J. Margrave, K. Yousefi, V. Choeurng, E. Davicioni, B.J. Trock, C.J. Kane, A. Pollack, J.W. Davis,
F.Y. Feng, E.A. Klein
Biopsy Decipher was able to predict metastasis and prostate cancer-specific
mortality from diagnostic biopsy specimens in a cohort of primarily intermediate-
and high-risk men regardless of type of first-line treatment.
853
Re: Association Between Direct-to-consumer Advertising and Testosterone Testing and Initiation in the United States, 2009–2013J.S. Jue, R. Ramasamy
854
Re: Incontinence Medication Response Relates to the Female Urinary MicrobiotaT.C. Chai
854
Re: Multicenter Investigation of the Micro-organisms Involved in Penile Prosthesis Infection: An Analysis of the Efficacy of the AUA and EAU Guidelines for Penile Prosthesis ProphylaxisW.J.G. Hellstrom, K.J. DeLay
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 5 , No v emb e r 2 0 1 7
Words ofWisdom
Surgery in Motion
Original Articles
Prostate Cancer